Crane NXT at Jefferies Global Industrials Conference 2026: growth stays in focus

Crane NXT said annual sales are approaching $2.0 billion, following 17% year-over-year growth to $1.8 billion in LTM revenue as of Q2 2026, and reiterated a mid-single-digit growth path toward roughly $2.5 billion in sales. Management highlighted mid-20% adjusted EBITDA margins, approximately 100% free-cash-flow conversion and record currency backlog extending more than two years. The Antares Vision integration is proceeding without material surprises, with a targeted 1,000bp EBITDA-margin expansion over five years from the mid-teens to the low-20% range. With leverage expected in the low-2x range and about $1 billion of 2027 dry powder, Crane NXT sees capacity for both acquisitions and potential buybacks while trading at 9.64x EBITDA.

Analysis

CXT’s upside is less about an undiscovered end-market and more about a potential quality re-rating once investors can underwrite the post-acquisition earnings base. At sub-10x EBITDA, the market appears to be capitalizing the company as a cyclical hardware industrial despite a mix increasingly tied to embedded security specifications, recurring software/service, and long-duration government procurement. If management converts the acquired Antares business toward the stated profitability profile, incremental EBITDA should carry a materially higher valuation multiple than the legacy portfolio; execution evidence, not conference messaging, is the gating item.

The key near-term issue is integration math. A 1,000bp margin bridge over five years implies roughly 200bp annually before considering revenue volatility, but the early savings cited are largely low-risk corporate-cost removal; the harder plant, procurement, and commercial actions may create disruption in 2027. Higher rates and a stronger dollar also matter disproportionately: CXT’s valuation support depends on FCF deleveraging and eventual capital returns, while international equipment demand can be deferred when customers face tighter financing.

Over 1-3 months, quarterly order conversion, Antares gross-margin progression, and buyback authorization are the catalysts capable of narrowing the valuation discount. Over 6-18 months, the differentiated outcome is that regulatory traceability can turn installed inspection equipment into a software/service annuity, creating cross-sell optionality that DHR’s life-sciences franchise has historically demonstrated can command premium economics. The contrarian risk is that the market is correctly discounting a collection of mature cash-handling and equipment assets, with software mix insufficient to change the consolidated multiple.

Falsify the constructive thesis if Antares margin fails to improve by at least 150-200bp over the next four reported quarters, organic growth falls below low-single digits excluding currency timing, or net leverage does not trend down despite claimed cash conversion. The broad risk-off backdrop argues against chasing a conference-driven move; use weakness around earnings or a market-led drawdown to establish exposure.

Key Decisions for Investors

• Initiate a starter long CXT on a 5-8% pullback from current levels; target 12-15x EBITDA over 12-18 months as integration proof and capital returns support re-rating, with downside protected by the cash-generative legacy base. Exit or reduce if next four-quarter Antares margin expansion is below 150bp.
• Use a relative-value pair: long CXT / short NOVT over 6-12 months, sized beta-neutral. CXT offers greater self-help margin optionality and valuation support; NOVT is a useful proxy for premium-valued precision/medical industrial exposure. Cover the short if NOVT’s organic growth accelerates above CXT by more than 500bp for two quarters.
• Do not underwrite repurchases until a formal authorization and post-deleveraging cash deployment are disclosed. Set an event alert for the next earnings release: confirmation of leverage reduction plus a buyback program would justify adding to CXT; absence of either keeps the position at starter size.
• Avoid using DHR as a direct short hedge: DHR’s scale, consumables mix, and life-sciences exposure make it a poor fundamental substitute. Use XLI or a small broad-industrial hedge only if macro rates continue repricing higher.